Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015246 | 0.87 | MEN1 (0.48) | CA1CA2HPGDCYP3A4TSHR | |
| SCHEMBL9621857 | 0.86 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9702457 | 0.82 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3756382 | 0.81 | TSHR (0.67) | CA1CA2CA9HPGDLMNA | |
| SCHEMBL3084512 | 0.80 | CYP3A4 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9622317 | 0.80 | CYP3A4 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11099557 | 0.79 | HCRTR1 (0.56) | CA1CA2CA7CA9LMNA | |
| SCHEMBL561706 | 0.78 | MEN1 (0.64) | CA1CA2CA9CA14HPGD | |
| SCHEMBL16998320 | 0.78 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9621858 | 0.77 | CYP3A4 (0.50) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114232338-A | Waterproof flame-retardant protective clothing and preparation process thereof | 安徽上造智能设备科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-10584202-B2 | Photovoltaic element | TORAY INDUSTRIES, INC (JP) | 2020-03-10 | — | — | US | claimed |
| CN-115353607-A | Preparation method of tough and flame-retardant bio-based polyurethane elastomer | 中国林业科学研究院林产化学工业研究所 | 2022-11-18 | — | — | CN | disclosed |
| CN-114232338-A | Waterproof flame-retardant protective clothing and preparation process thereof | 安徽上造智能设备科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10584202-B2 | Photovoltaic element | TORAY INDUSTRIES, INC (JP) | 2020-03-10 | — | — | US | disclosed |
| EP-3133659-B1 | METHOD FOR FORMING AN ELECTRON EXTRACTION LAYER | TORAY INDUSTRIES (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3133659-A1 | PHOTOVOLTAIC ELEMENT | Toray Industries, Inc. (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20170033304-A1 | PHOTOVOLTAIC ELEMENT | TORAY INDUSTRIES, INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| WO-2012103990-A1 | PHOSPHORAMIDATES OF MONOSACCHARIDES | BIOIBERICA, S.A. (ES) | 2012-08-09 | — | — | WO | disclosed |
| EP-2471802-A1 | Phosphoramidates of monosaccharides | Bioiberica, S.A. (ES) | 2012-07-04 | — | — | EP | disclosed |
| US-20070275910-A1 | Phosphoramidate Derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070275910-A1 | Phosphoramidate Derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1709056-A1 | PHOSPHORAMIDATE DERIVATIVES | University College Cardiff Consultants Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070944-A1 | PHOSPHORAMIDATE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-08-04 | — | — | WO | disclosed |
| EP-0019401-B1 | PROCESS FOR PREPARING ENAMINE DERIVATIVES, COMPOUNDS SO PRODUCED AND PROCESS FOR PREPARING A 3-HYDROXY-CEPHALOSPORIN | Lilly Industries Limited (GB) | 1984-03-21 | — | — | EP | disclosed |
| US-4301280-A | Preparation of 3-substituted cephalosporins | LILLY INDUSTRIES LIMITED (GB) | 1981-11-17 | — | — | US | disclosed |
| EP-0019401-A1 | Process for preparing enamine derivatives, compounds so produced and process for preparing a 3-hydroxy-cephalosporin | Lilly Industries Limited (GB) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | CA1 4798/4885CA2 4632/4885CA7 4631/4885 |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | CA1 4877/4885CA2 4572/4885CA7 4538/4885 |
| US-20070275910-A1 | Phosphoramidate Derivatives | HRH4, HRH3, NR1H4 | CA1 1019/4885CA2 689/4885CA7 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.